VAXX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 15:59):

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States...

Stats
Today's Volume	1.24M
Average Volume	2.28M
Market Cap	10.27M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $0 ) 2024-06-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0.00100 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-01	Ray Sumita	Buy	425 000	Employee Stock option (right to buy)
2023-11-03	Paula Molina Rene	Buy	0
2023-10-02	Powchik Peter	Buy	159 744	Stock option (right to buy)
2023-10-01	Ray Sumita	Buy	0
2023-09-06	Prime Movers Lab Fund I Lp	Sell	5 308	Class A Common Stock

INSIDER POWER
55.17
Last 91 transactions
Buy: 6 350 518 \| Sell: 2 608 586

Volume Correlation

Long: -0.02 (neutral)

Short: -0.71 (moderate negative)

Signal:(49.568) Neutral

Vaxxinity, Inc. Correlation

10 Most Positive Correlations
MRNS	0.942
HOFT	0.94
BBCP	0.933
HUGE	0.929
MBIO	0.924
ALLR	0.922
DUNE	0.92
CIIG	0.918
RGP	0.918
QTRX	0.916

10 Most Negative Correlations
CHCI	-0.95
RANI	-0.948
CSTE	-0.928
GAIA	-0.921
GRIN	-0.917
ABIO	-0.912
CADL	-0.906
NYMX	-0.905
LSAK	-0.903
LE	-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaxxinity, Inc. Correlation - Currency/Commodity

0.46
( neutral )

0.29
( neutral )

0.00
( neutral )

-0.53
( weak negative )

Vaxxinity, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2023
Revenue:	$0
Gross Profit:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2022
Revenue:	$0
Gross Profit:	$-1.68M (0.00 %)
EPS:	$-0.600

FY	2021
Revenue:	$66 000.00
Gross Profit:	$-1.87M (-2 834.85 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Vaxxinity, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.